
  
    
      
        Background_NNP
        Patients_NNS on_IN dialysis_NN have_VBP more_RBR coronary_JJ artery_NN disease_NN
        (_( CAD_NNP )_) and_CC CAD-related_NNP mortality_NN than_IN the_DT general_JJ population_NN
        [_NN 1_CD ]_NN ._. Elevated_NNP low-density_NN lipoprotein_NN (_( LDL_NNP )_) cholesterol_NN
        level_NN is_VBZ an_DT independent_JJ risk_NN factor_NN for_IN patients_NNS with_IN end_NN
        stage_NN renal_JJ disease_NN (_( ESRD_NNP )_) [_NN 2_CD ]_NN ._. The_DT
        3_CD -_: hydroxy-_NN 3_CD methylglutaryl_NN coenzyme_NN A_DT (_( HMG-CoA_NNP )_) reductase_NN
        inhibitors_NNS (_( statins_NNS )_) have_VBP been_VBN associated_VBN with_IN decreased_VBD
        all-cause_JJ mortality_NN in_IN dialysis_NN patients_NNS in_IN a_DT
        registry-based_JJ study_NN [_NN 3_CD ]_NN and_CC clinical_JJ trials_NNS are_VBP underway_NN
        to_TO confirm_VB this_DT benefit_NN [_NN 4_CD 5_CD ]_NN ._.
        Mortality_NNP benefits_NNS of_IN statins_NNS has_VBZ been_VBN attributed_VBN to_TO
        lower_JJR lipid_NN levels_NNS ,_, but_CC recent_JJ reports_NNS indicate_VBP that_IN
        statins_NNS may_MD reduce_VB cardiovascular_JJ risk_NN by_IN other_JJ mechanisms_NNS ,_,
        [_NN 6_CD 7_CD ]_NN and_CC may_MD also_RB reduce_VB cancer-related_JJ mortality_NN [_NN 8_CD ]_NN
        ._. Consensus_NNP is_VBZ growing_VBG for_IN statin_NN use_NN in_IN all_DT ESRD_NNP patients_NNS
        with_IN atherosclerotic_JJ disease_NN or_CC diabetes_NN [_NN 9_CD ]_NN ._. If_IN used_VBD
        this_DT way_NN ,_, over_IN 60_CD %_NN of_IN all_DT dialysis_NN patients_NNS might_MD be_VB
        eligible_JJ for_IN statins_NNS [_NN 10_CD ]_NN ._. Despite_IN an_DT acceptable_JJ safety_NN
        profile_NN [_NN 6_CD 11_CD ]_NN ,_, fewer_JJR than_IN 10_CD %_NN of_IN dialysis_NN patients_NNS were_VBD
        prescribed_VBN statins_NNS according_VBG to_TO USRDS_NNP and_CC Canadian_JJ studies_NNS ,_,
        [_NN 3_CD 12_CD ]_NN even_RB in_IN known_VBN coronary_JJ heart_NN disease_NN [_NN 13_CD ]_NN ._.
        Despite_IN differences_NNS in_IN the_DT pattern_NN of_IN dyslipidemia_NN and_CC
        cardiovascular_JJ disease_NN in_IN ESRD_NNP patients_NNS compared_VBN with_IN the_DT
        general_JJ population_NN ,_, current_JJ use_NN of_IN statins_NNS focus_VBP on_IN
        treating_VBG elevated_VBD LDL_NNP cholesterol_NN levels_NNS ._. National_NNP
        Cholesterol_NNP Education_NNP Program_NNP (_( NCEP_NNP )_) guidelines_NNS recommend_VBP a_DT
        target_NN LDL_NNP cholesterol_NN of_IN 100_CD mg_NN /_NN dl_NN in_IN high-risk_JJ groups_NNS [_NN
        14_CD ]_NN ._. Pharmacists_NNP are_VBP becoming_VBG more_RBR involved_JJ in_IN managing_VBG a_DT
        variety_NN of_IN chronic_JJ diseases_NNS [_NN 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN ._. For_IN lipid_NN
        lowering_VBG ,_, a_DT team_NN approach_NN is_VBZ more_RBR effective_JJ in_IN the_DT
        ambulatory_JJ care_NN setting_VBG than_IN management_NN by_IN a_DT physician_NN [_NN 20_CD
        21_CD ]_NN ,_, but_CC there_EX are_VBP no_DT published_VBN reports_NNS on_IN using_VBG this_DT
        approach_NN in_IN a_DT dialysis_NN population_NN ._. Here_RB ,_, we_PRP describe_VBP the_DT
        effectiveness_NN and_CC feasibility_NN of_IN our_PRP$ multidisciplinary_JJ
        lipid_NN management_NN program_NN using_VBG the_DT specific_JJ skills_NNS of_IN
        pharmacist_NN ,_, dietitian_NN and_CC nephrologist_NN in_IN hemodialysis_NNS
        patients_NNS ._.
        Walter_NNP Reed_NNP Army_NNP Medical_NNP Center_NNP (_( WRAMC_NNP )_) is_VBZ a_DT 235_CD -_: bed_NN ,_,
        tertiary-care_JJ military_JJ hospital_NN with_IN 25_CD -_: 30_CD chronic_JJ dialysis_NN
        patients_NNS ._. Prior_RB to_TO implementation_NN of_IN our_PRP$ program_NN ,_, two_CD
        formulary_JJ statins_NNS (_( simvastatin_NN and_CC cerivastatin_NN )_) were_VBD
        available_JJ ._. A_DT hospital-wide_JJ switch_NN to_TO these_DT statins_NNS was_VBD
        mandated_VBN by_IN the_DT Department_NNP of_IN Defense_NNP Pharmacoeconomic_NNP
        Center_NNP to_TO reduce_VB cost_NN and_CC provide_VB uniformity_NN ._. A_DT Statin_NNP
        Formulary_NNP Conversion_NNP Clinic_NNP switched_VBD all_DT patients_NNS to_TO
        cerivastatin_NN (_( preferred_VBN agent_NN )_) or_CC simvastatin_NN between_IN
        January-_NNP April_NNP 2000_CD [_NN 22_CD ]_NN ._. HD_NNP patients_NNS were_VBD given_VBN
        simvastatin_NN during_IN the_DT conversion_NN due_JJ to_TO dose_NN adjustment_NN
        recommendations_NNS for_IN cerivastatin_NN in_IN patients_NNS with_IN renal_JJ
        insufficiency_NN and_CC lack_NN of_IN experience_NN with_IN this_DT drug_NN in_IN
        ESRD_NNP ._. Consequently_RB ,_, there_EX were_VBD several_JJ dialysis_NN patients_NNS
        taking_VBG non-formulary_JJ statins_NNS when_WRB our_PRP$ HD_NNP lipid_NN management_NN
        program_NN began_VBD ,_, because_IN they_PRP had_VBD failed_VBN to_TO reach_VB goals_NNS on_IN
        formulary_JJ statins_NNS ._.
        Our_PRP$ program_NN was_VBD designed_VBN as_IN an_DT ongoing_JJ lipid_NN management_NN
        program_NN ,_, directed_VBN by_IN the_DT clinical_JJ pharmacist_NN assigned_VBN to_TO
        the_DT Nephrology_NNP Service_NNP ._. The_DT clinical_JJ pharmacist_NN received_VBD
        approval_NN from_IN the_DT hospital_NN credentials_NNS committee_NN ,_, the_DT
        pharmacy_NN &_CC therapeutics_NNS committee_NN ,_, and_CC the_DT director_NN of_IN
        dialysis_NN to_TO prescribe_VB and_CC make_VB dosage_NN adjustments_NNS and_CC order_NN
        laboratory_NN tests_NNS as_IN per_IN a_DT lipid_NN management_NN guideline_NN ._. The_DT
        WRAMC_NNP Human_NNP Use_NNP Committee_NNP approved_VBN a_DT 6_CD -_: month_NN retrospective_NN
        review_NN of_IN the_DT program_NN in_IN April_NNP 2001_CD ._.
      
      
        Methods_NNP
        
          Guideline_NNP development_NN
          A_DT guideline_NN for_IN management_NN of_IN hyperlipidemia_NN and_CC
          conversion_NN to_TO formulary_JJ statin_NN in_IN HD_NNP patients_NNS was_VBD
          developed_VBN jointly_RB between_IN the_DT nephrologists_NNS ,_, clinical_JJ
          pharmacist_NN and_CC renal_JJ dietitian_NN before_IN program_NN
          implementation_NN (_( Table_NNP 1_LS )_) ._. Patients_NNS were_VBD converted_VBN at_IN the_DT
          start_NN of_IN the_DT program_NN ,_, or_CC whenever_WRB they_PRP initiated_VBD
          dialysis_NN ._. Only_RB simvastatin_NN and_CC atorvastatin_NN were_VBD included_VBN
          in_IN the_DT guideline_NN ._. Atorvastatin_NNP was_VBD prescribed_VBN for_IN
          patients_NNS who_WP failed_VBD simvastatin_NN ._.
        
        
          Inclusion_NNP /_NN exclusion_NN criteria_NNS
          All_DT WRAMC_NNP chronic_JJ hemodialysis_NNS patients_NNS were_VBD eligible_JJ ._.
          Exclusion_NNP criteria_NNS included_VBD age_NN <_NN 18_CD years_NNS ,_, acute_JJ
          renal_JJ failure_NN ,_, pregnancy_NN or_CC nursing_NN ,_, use_NN of_IN cyclosporine_NN ,_,
          tacrolimus_JJ ,_, or_CC gemfibrozil_NN ,_, elevated_VBD liver_NN associated_VBN
          enzymes_NNS (_( LAEs_NNP )_) ,_, and_CC allergy_NN to_TO statins_NNS ._. All_DT 25_CD
          hemodialysis_NNS patients_NNS met_VBD criteria_NNS for_IN inclusion_NN in_IN
          September_NNP 2000_CD when_WRB the_DT program_NN was_VBD implemented_VBN ._. An_DT
          additional_JJ patient_NN who_WP initiated_VBD dialysis_NN during_IN the_DT
          study_NN period_NN was_VBD included_VBN ,_, for_IN a_DT total_NN of_IN 26_CD
          patients_NNS ._.
        
        
          Laboratory_NNP monitoring_VBG
          Blood_NNP tests_NNS were_VBD routinely_RB drawn_VBN every_DT 4_CD weeks_NNS for_IN
          monitoring_NN of_IN anemia_NN ,_, calcium_NN and_CC phosphate_NN control_NN ,_,
          LAEs_NNP ,_, nutritional_JJ indices_NNS ,_, and_CC dialysis_NN adequacy_NN ._. The_DT
          pharmacist_NN ordered_VBD a_DT non-fasting_JJ lipid_NN profile_NN for_IN each_DT
          patient_NN in_IN accordance_NN with_IN the_DT guideline_NN (_( e_SYM ._. g_SYM ._. every_DT 8_CD
          weeks_NNS ,_, every_DT 4_CD months_NNS ,_, or_CC yearly_JJ depending_VBG on_IN monitoring_VBG
          requirement_NN )_) ._. The_DT lipid_NN profile_NN included_VBD total_JJ
          cholesterol_NN (_( TC_NNP )_) ,_, LDL_NNP cholesterol_NN ,_, triglycerides_NNS ,_, and_CC
          high-density_JJ lipoprotein_NN (_( HDL_NNP )_) cholesterol_NN ._. Blood_NNP was_VBD
          analyzed_VBN in_IN the_DT WRAMC_NNP clinical_JJ chemistry_NN laboratory_NN using_VBG
          the_DT Roche_NNP COBAS_NNP Integra_NNP 700_CD System_NNP ®_NN (_( Roche_NNP Diagnostic_NNP
          System_NNP ,_, Somerville_NNP ,_, NJ_NNP )_) ._. Roche_NNP Precinorm_NNP ®_NN and_CC Precipath_NNP
          ®_NN reagents_NNS were_VBD used_VBN for_IN quality_NN control_NN for_IN HDL_NNP and_CC LDL_NNP
          cholesterol_NN results_NNS ._. Bio-rad_NNP Liquicheck_NNP ®_NN Level_NNP 1_CD and_CC
          Level_NNP 2_CD ,_, (_( Bio-rad_NNP Diagnostic_NNP Group_NNP ,_, Irvine_NNP ,_, CA_NNP )_) ,_, were_VBD
          used_VBN for_IN quality_NN control_NN of_IN TC_NNP and_CC triglyceride_NN
          measurements_NNS ._. Calibration_NNP was_VBD done_VBN daily_RB ._. A_DT non-fasting_JJ
          lipid_NN profile_NN was_VBD acceptable_JJ for_IN LDL_NNP cholesterol_NN and_CC TC_NNP
          measurement_NN because_IN the_DT assay_NN measured_VBD parameters_NNS
          directly_RB ._. If_IN the_DT non-fasting_JJ triglyceride_NN level_NN was_VBD ≥_NN 200_CD
          mg_NN /_NN dL_NN ,_, the_DT physician_NN was_VBD notified_VBN ,_, and_CC a_DT fasting_VBG
          triglyceride_NN level_NN was_VBD ordered_VBN at_IN his_PRP$ /_NN her_PRP$ discretion_NN ._.
        
        
          Patient_NNP counseling_NN and_CC referral_NN
          After_IN review_NN of_IN each_DT lipid_NN profile_NN ,_, the_DT pharmacist_NN
          provided_VBD verbal_JJ instruction_NN ,_, statin_NN information_NN handouts_NNS
          (_( at_IN drug_NN initiation_NN or_CC change_NN )_) ,_, and_CC a_DT "_'' Personal_NNP
          Cholesterol_NNP Management_NNP Report_NNP "_'' to_TO each_DT patient_NN ._. This_DT
          reported_VBD the_DT patient_NN 's_POS own_JJ lipid_NN profile_NN result_NN and_CC goal_NN
          values_NNS ,_, as_RB well_RB as_IN the_DT new_JJ statin_NN dose_NN (_( or_CC dose_NN to_TO be_VB
          continued_VBN )_) ._. This_DT report_NN also_RB explained_VBD the_DT importance_NN of_IN
          cholesterol_NN control_NN and_CC listed_VBN common_JJ side_NN effects_NNS of_IN
          statins_NNS ._. At_IN the_DT time_NN of_IN each_DT report_NN ,_, the_DT pharmacist_NN
          explained_VBD the_DT lipid_NN profile_NN results_NNS ,_, asked_VBD about_IN side_NN
          effects_NNS ,_, and_CC reviewed_VBD the_DT patient_NN 's_POS drug_NN regimen_NN for_IN
          medication_NN compliance_NN and_CC new_JJ or_CC potential_JJ drug_NN
          interactions_NNS ._. The_DT pharmacist_NN also_RB gave_VBD the_DT patient_NN a_DT new_JJ
          prescription_NN with_IN refills_NNS to_TO last_VB until_IN the_DT next_RB
          scheduled_VBN lipid_NN panel_NN ._. Patients_NNS needing_VBG dietary_JJ
          reinforcement_NN were_VBD referred_VBN to_TO the_DT renal_JJ dietitian_NN ._.
          Adverse_JJ reactions_NNS or_CC potential_JJ drug_NN interactions_NNS were_VBD
          brought_VBN to_TO the_DT nephrologist_NN 's_POS attention_NN ._.
        
        
          Documentation_NNP and_CC data_NNS collection_NN
          The_DT clinical_JJ pharmacist_NN documented_VBN all_DT interventions_NNS
          and_CC referrals_NNS using_VBG an_DT Excel_NNP ®_NN spreadsheet_NN (_( Microsoft_NNP ,_,
          Redmond_NNP ,_, WA_NNP )_) ._. Individual_JJ reports_NNS were_VBD generated_VBN that_WDT gave_VBD
          lipid_NN profile_NN and_CC LAE_NNP results_NNS ,_, any_DT adverse_JJ drug_NN reaction_NN
          or_CC drug_NN interaction_NN ,_, dosage_NN adjustments_NNS made_VBN ,_, and_CC the_DT
          date_NN of_IN the_DT next_RB scheduled_VBN lipid_NN profile_NN ._. This_DT report_NN was_VBD
          placed_VBN in_IN the_DT patient_NN 's_POS HD_NNP chart_NN after_IN each_DT lipid_NN
          profile_NN ._. A_DT copy_NN was_VBD given_VBN to_TO each_DT nephrologist_NN ._.
          Lipid_NNP data_NNS was_VBD tabulated_JJ monthly_NN by_IN the_DT pharmacist_NN and_CC
          submitted_VBN to_TO the_DT nephrology_NN service_NN quality_NN improvement_NN
          coordinator_NN ,_, the_DT medical_JJ director_NN of_IN dialysis_NN ,_, and_CC the_DT
          chief_NN of_IN nephrology_NN for_IN ongoing_JJ program_NN evaluation_NN ._. Data_NNP
          submitted_VBD included_VBD the_DT number_NN of_IN patients_NNS followed_VBN ,_,
          number_NN of_IN patients_NNS at_IN LDL_NNP cholesterol_NN goal_NN ,_, average_JJ LDL_NNP
          cholesterol_NN and_CC total_JJ cholesterol_NN ,_, number_NN of_IN adverse_JJ drug_NN
          reactions_NNS and_CC potential_JJ drug_NN interactions_NNS identified_VBN ._. HDL_NNP
          data_NNS was_VBD not_RB analyzed_VBN or_CC included_VBD as_IN part_NN of_IN the_DT
          guideline_NN ._.
        
        
          Statistical_NNP analysis_NN
          Data_NNP was_VBD tabulated_JJ in_IN Microsoft_NNP Excel_NNP ®_NN and_CC analyzed_VBD
          using_VBG SigmaStat_NNP ®_NN (_( SPSS_NNP ,_, Chicago_NNP ,_, IL_NNP )_) ._. Fisher_NNP exact_JJ test_NN
          was_VBD used_VBN for_IN categorical_JJ variables_NNS and_CC paired_VBN Student_NNP 's_POS
          t-test_JJ was_VBD used_VBN for_IN continuous_JJ parametric_JJ variables_NNS ._.
          Wilcoxon_NNP signed-rank_JJ test_NN was_VBD used_VBN for_IN continuous_JJ
          variables_NNS that_WDT were_VBD not_RB normally_RB distributed_VBN ._. A_DT p-value_JJ
          of_IN <_NN 0_CD ._. 05_CD was_VBD considered_VBN statistically_RB
          significant_JJ ._.
        
      
      
        Results_NNS
        Patient_NNP demographics_NNS are_VBP shown_VBN in_IN Table_NNP 2_CD ._. After_IN 6_CD
        months_NNS ,_, 23_CD of_IN 26_CD patients_NNS (_( 88_CD %_NN )_) had_VBD reached_VBN target_NN LDL_NNP
        cholesterol_NN (_( Figure_NN 1_LS )_) ,_, compared_VBN with_IN 15_CD patients_NNS (_( 58_CD %_NN )_) at_IN
        the_DT start_NN of_IN the_DT program_NN (_( p_NN =_SYM 0_CD ._. 015_CD )_) ._. Mean_VB LDL_NNP cholesterol_NN
        decreased_VBD 16_CD ._. 7_CD %_NN ,_, from_IN 96_CD ±_NN 5_CD to_TO 80_CD ±_NN 3_CD mg_NN /_NN dl_NN (_( p_NN <_NN
        0_CD ._. 001_CD )_) ,_, and_CC mean_VB total_JJ cholesterol_NN decreased_VBD 11_CD ._. 1_LS %_NN ,_, from_IN
        170_CD ±_NN 7_CD to_TO 151_CD ±_NN 4_CD mg_NN /_NN dl_NN (_( p_NN =_SYM 0_CD ._. 004_CD )_) ._.
        Eight_CD adverse_JJ drug_NN reactions_NNS were_VBD identified_VBN in_IN 7_CD
        patients_NNS ._. Four_CD patients_NNS (_( 15_CD ._. 4_LS %_NN )_) experienced_VBN musculoskeletal_NN
        symptoms_NNS ,_, 2_CD of_IN which_WDT had_VBD muscle_NN aches_NNS and_CC weakness_NN (_( hand_NN ,_,
        arm_NN and_CC back_RB muscles_NNS )_) ._. Creatine_NNP phosphokinase_NN (_( CPK_NNP )_) levels_NNS
        were_VBD normal_JJ in_IN both_DT cases_NNS ._. Drug_NN therapy_NN was_VBD not_RB interrupted_VBN
        in_IN either_DT case_NN ,_, and_CC other_JJ etiologies_NNS for_IN the_DT symptoms_NNS were_VBD
        pursued_VBN ._. The_DT other_JJ 2_CD patients_NNS reported_VBD shoulder_NN soreness_NN ,_,
        thought_VBD related_VBN to_TO exercise_VB ,_, and_CC leg_NN cramping_VBG ,_, thought_VBD to_TO
        be_VB due_JJ to_TO the_DT previous_JJ day_NN 's_POS dialysis_NN ._. CPK_NNP levels_NNS were_VBD not_RB
        obtained_VBN and_CC the_DT symptoms_NNS spontaneously_RB resolved_VBN after_IN
        several_JJ days_NNS ._.
        Two_CD patients_NNS (_( 7_CD ._. 6_CD %_NN )_) experienced_VBD an_DT increase_NN in_IN LAEs_NNP ._. A_DT
        3_CD -_: fold_VB increase_NN in_IN serum_NN transaminases_NNS occurred_VBD in_IN one_CD
        patient_NN who_WP was_VBD initiated_VBN on_IN simvastatin_NN 20_CD mg_NN qd_NN during_IN
        the_DT program_NN ._. The_DT drug_NN was_VBD discontinued_VBN ._. One_CD patient_NN had_VBD a_DT
        mild_JJ transient_JJ increase_NN in_IN alkaline_NN phosphatase_NN ,_, from_IN 115_CD
        IU_NNP /_NN L_NNP to_TO 131_CD IU_NNP /_NN L_NNP ,_, when_WRB starting_VBG statin_NN therapy_NN ._. The_DT drug_NN
        was_VBD not_RB discontinued_VBN and_CC the_DT level_NN returned_VBD to_TO baseline_NN
        within_IN 2_CD months_NNS ._.
        Diarrhea_NNP or_CC gastrointestinal_NN upset_VBN was_VBD reported_VBN in_IN 2_CD
        patients_NNS (_( 7_CD ._. 6_CD %_NN )_) ._. Relationship_NNP to_TO the_DT statin_NN was_VBD unclear_JJ ._.
        One_CD patient_NN was_VBD switched_VBN from_IN simvastatin_NN to_TO atorvastatin_NN
        with_IN slight_JJ improvement_NN ._. In_IN the_DT second_JJ patient_NN ,_, symptoms_NNS
        resolved_VBN when_WRB acetaminophen_NN with_IN codeine_NN was_VBD
        discontinued_VBN ._.
        Eight_CD potential_JJ drug_NN interactions_NNS were_VBD identified_VBN ._.
        Physicians_NNPS were_VBD alerted_VBD to_TO monitor_VB for_IN myopathy_NN and_CC changes_NNS
        in_IN international_JJ normalized_JJ ratio_NN (_( INR_NNP )_) in_IN 3_CD patients_NNS
        taking_VBG warfarin_NN because_IN of_IN potential_JJ for_IN cytochrome_NN P_NN 450_CD
        3_CD A_DT 4_CD competition_NN ._. Other_JJ drugs_NNS with_IN cytochrome_NN P_NN 450_CD
        interaction_NN potential_NN were_VBD identified_VBN ,_, including_VBG verapamil_NN
        (_( 2_CD patients_NNS )_) ,_, and_CC diltiazem_NN (_( 1_CD patient_NN )_) ._. Other_JJ drug_NN
        interactions_NNS of_IN a_DT different_JJ /_NN unknown_JJ mechanism_NN included_VBD
        digoxin_NN and_CC levothyroxine_NN (_( 1_CD patient_NN each_DT )_) ._. No_DT drug_NN
        interaction_NN resulted_VBD in_IN an_DT adverse_JJ event_NN or_CC discontinuation_NN
        of_IN therapy_NN ._.
        Fourteen_CD patients_NNS (_( 54_CD %_NN )_) were_VBD on_IN statins_NNS at_IN the_DT start_NN of_IN
        the_DT program_NN ,_, 4_CD of_IN whom_WP were_VBD receiving_VBG non-formulary_JJ
        statins_NNS ._. (_( 1_CD cerivastatin_NN :_: 3_CD pravastatin_NN ._. )_) Four_CD patients_NNS
        were_VBD on_IN simvastatin_NN 20_CD mg_NN qd_NN ;_: 6_CD patients_NNS were_VBD on_IN
        simvastatin_NN 40_CD mg_NN qd_NN ._. At_IN 6_CD months_NNS ,_, 15_CD (_( 58_CD %_NN )_) were_VBD on_IN
        statins_NNS ._. Of_IN these_DT ,_, 7_CD patients_NNS were_VBD on_IN simvastatin_NN 20_CD mg_NN qd_NN ,_,
        3_CD patients_NNS were_VBD on_IN simvastatin_NN 40_CD mg_NN qd_NN ,_, and_CC 2_CD patients_NNS
        were_VBD taking_VBG simvastatin_NN 80_CD mg_NN qd_NN ._. One_CD patient_NN each_DT was_VBD
        taking_VBG atorvastatin_NN 40_CD mg_NN qd_NN and_CC 80_CD mg_NN qd_NN ._. Two_CD patients_NNS
        were_VBD initiated_VBN on_IN statins_NNS during_IN the_DT period_NN studied_VBD ,_, one_CD of_IN
        which_WDT was_VBD discontinued_VBN at_IN 6_CD months_NNS due_JJ to_TO increased_VB LAEs_NNP ._.
        During_IN the_DT 6_CD -_: month_NN period_NN ,_, 1_CD patient_NN died_VBD from_IN
        cardiovascular_JJ disease_NN ._. Her_PRP$ LDL_NNP cholesterol_NN and_CC TC_NNP were_VBD not_RB
        elevated_VBD (_( 55_CD mg_NN /_NN dl_NN and_CC 146_CD mg_NN /_NN dl_NN ,_, respectively_RB )_) ._. Three_CD
        patients_NNS received_VBD renal_JJ transplants_NNS ._.
        Table_NNP 3_CD summarizes_NNS the_DT interventions_NNS made_VBN by_IN the_DT
        pharmacist_NN ._. All_DT patients_NNS received_VBD medication_NN teaching_NN and_CC
        compliance_NN assessment_NN at_IN each_DT encounter_NN ._. Most_JJS patient_NN
        encounters_VBZ resulted_VBN in_IN continuation_NN of_IN current_JJ therapy_NN
        (_( including_VBG those_DT who_WP were_VBD at_IN goal_NN LDL_NNP cholesterol_NN with_IN
        non-pharmacological_JJ therapy_NN )_) ._. Statins_NNP were_VBD stopped_VBN in_IN 1_CD
        patient_NN because_IN of_IN low_JJ LDL_NNP cholesterol_NN level_NN (_( 37_CD mg_NN /_NN dl_NN )_) ._.
        The_DT renal_JJ dietitian_NN was_VBD consulted_VBN 3_CD times_NNS for_IN specific_JJ
        dietary_JJ counseling_NN relating_VBG to_TO cholesterol_NN control_NN and_CC
        compliance_NN ._.
        Overall_RB nutritional_JJ status_NN remained_VBD stable_JJ ._. Median_JJ
        albumin_NN at_IN study_NN entry_NN was_VBD 3_CD ._. 73_CD g_SYM /_NN dL_NN (_( range_NN 2_CD ._. 3_CD -_: 4_CD ._. 5_CD
        g_SYM /_NN dL_NN )_) ,_, vs_NNS ._. 3_CD ._. 86_CD g_SYM /_NN dL_NN (_( range_NN 2_CD ._. 9_CD -_: 4_CD ._. 7_CD g_SYM /_NN dL_NN )_) at_IN 6_CD months_NNS (_( p_NN
        =_SYM 0_CD ._. 345_CD )_) ._.
      
      
        Discussion_NNP
        This_DT study_NN shows_VBZ that_WDT improved_VBD LDL_NNP cholesterol_NN control_NN
        can_MD be_VB achieved_VBN in_IN chronic_JJ HD_NNP patients_NNS using_VBG a_DT
        multidisciplinary_JJ pharmacist-directed_JJ lipid_NN program_NN ._.
        Hemodialysis_NNP populations_NNS may_MD be_VB ideal_JJ for_IN this_DT program_NN
        because_IN of_IN convenient_JJ blood_NN sampling_VBG and_CC frequent_JJ provider_NN
        contact_NN ._. Program_NN costs_NNS included_VBD the_DT minimal_JJ cost_NN of_IN patient_NN
        pamphlets_NNS ,_, and_CC the_DT cost_NN of_IN additional_JJ pharmacist_NN time_NN ._. We_PRP
        estimated_VBD that_IN 8_CD -_: 12_CD additional_JJ hours_NNS /_NN month_NN were_VBD required_VBN
        for_IN pharmacist_NN interventions_NNS ,_, documentation_NN and_CC compiling_VBG
        reports_NNS ._. The_DT program_NN did_VBD not_RB incur_VB additional_JJ laboratory_NN
        costs_NNS ,_, since_IN lipid-monitoring_JJ guidelines_NNS were_VBD those_DT of_IN the_DT
        NCEP_NNP ._. Overall_RB ,_, the_DT program_NN was_VBD well_RB accepted_VBN by_IN nurses_NNS ,_,
        nephrologists_NNS and_CC patients_NNS ._.
        Side_NN effects_NNS were_VBD minimal_JJ during_IN the_DT period_NN ,_, and_CC several_JJ
        potential_JJ drug_NN interactions_NNS were_VBD avoided_VBN ._. Saltissi_NNP ,_, et_CC al_NN [_NN
        11_CD ]_NN recently_RB reported_VBD the_DT tolerability_NN and_CC effectiveness_NN
        of_IN simvastatin_NN in_IN doses_NNS of_IN 5_CD -_: 20_CD mg_NN in_IN lowering_VBG LDL_NNP and_CC
        non-_NN HDL_NNP cholesterol_NN in_IN dialysis_NN patients_NNS ._. Although_IN the_DT
        majority_NN of_IN our_PRP$ patients_NNS required_VBD simvastatin_NN 20_CD mg_NN to_TO
        reach_VB LDL_NNP goal_NN ,_, simvastatin_NN in_IN higher_JJR doses_NNS and_CC
        atorvastatin_NN were_VBD used_VBN and_CC well_RB tolerated_JJ ,_, with_IN dose_NN
        changes_NNS made_VBN in_IN a_DT timely_JJ fashion_NN ,_, undoubtedly_RB contributing_VBG
        to_TO program_NN effectiveness_NN ._. It_PRP is_VBZ unknown_JJ whether_IN a_DT longer_JJR
        treatment_NN period_NN with_IN these_DT doses_NNS would_MD have_VB produced_VBN more_JJR
        side_NN effects_NNS ._. One_CD complicating_VBG factor_NN of_IN statin_NN therapy_NN in_IN
        HD_NNP patients_NNS is_VBZ the_DT high_JJ prevalence_NN of_IN hepatitis_NNP B_NNP and_CC C_NNP ,_,
        making_VBG it_PRP difficult_JJ to_TO differentiate_VB hepatitis-induced_JJ
        increases_NNS in_IN LAEs_NNP from_IN those_DT due_NN to_TO the_DT statin_NN ._. This_DT was_VBD
        not_RB an_DT issue_NN in_IN our_PRP$ study_NN ,_, although_IN several_JJ patients_NNS were_VBD
        positive_JJ for_IN hepatitis_NN ._. Although_IN CPK_NNP levels_NNS were_VBD not_RB
        measured_VBN at_IN baseline_NN ,_, in_IN patients_NNS with_IN musculoskeletal_NN
        symptoms_NNS ,_, this_DT value_NN was_VBD found_VBN to_TO be_VB normal_JJ ._. Of_IN note_NN ,_, the_DT 3_CD
        patients_NNS who_WP did_VBD not_RB reach_VB LDL_NNP cholesterol_NN goal_NN were_VBD not_RB
        those_DT who_WP experienced_VBD side_NN effects_NNS requiring_VBG
        discontinuation_NN of_IN therapy_NN ._. LDL_NNP levels_NNS in_IN these_DT patients_NNS
        were_VBD near_IN goal_NN and_CC ranged_VBD from_IN 102_CD -_: 105_CD mg_NN /_NN dl_NN ._.
        Limitations_NNPS of_IN the_DT study_NN include_VBP the_DT small_JJ number_NN of_IN
        patients_NNS and_CC lack_NN of_IN a_DT control_NN group_NN ._. Since_IN patients_NNS began_VBD
        the_DT program_NN after_IN "_'' physician_NN only_RB "_'' lipid_NN management_NN ,_, one_CD
        presumes_VBZ by_IN the_DT improvement_NN in_IN lipid_NN levels_NNS and_CC number_NN of_IN
        patients_NNS at_IN LDL_NNP cholesterol_NN goal_NN that_IN the_DT team_NN approach_NN was_VBD
        more_RBR favorable_JJ ._. That_DT 54_CD %_NN of_IN patients_NNS were_VBD on_IN statins_NNS and_CC
        58_CD %_NN were_VBD at_IN goal_NN LDL_NNP cholesterol_NN at_IN the_DT beginning_NN of_IN the_DT
        program_NN can_MD be_VB attributed_VBN to_TO the_DT close_NN monitoring_VBG by_IN
        nephrologists_NNS in_IN a_DT fellowship_NN program_NN and_CC the_DT pharmacy-run_JJ
        statin_NN conversion_NN clinic_NN ._. Even_RB so_RB ,_, these_DT results_NNS improved_VBN
        after_IN implementing_VBG the_DT multidisciplinary_JJ approach_NN ._.
        Although_IN compliance_NN was_VBD not_RB documented_VBN by_IN pill_NN count_NN ,_,
        the_DT pharmacist_NN ,_, with_IN access_NN to_TO computer_NN databases_NNS ,_, assessed_VBN
        drug_NN adherence_NN by_IN refill_NN frequency_NN ,_, patient_NN interviews_NNS ,_, and_CC
        lab_NN results_NNS ._. In_IN addition_NN to_TO increasing_VBG compliance_NN ,_,
        including_VBG patients_NNS in_IN therapeutic_JJ decision-making_NN may_MD be_VB
        cost-effective_JJ [_NN 23_CD ]_NN ._. The_DT patient_NN handouts_NNS with_IN lipid_NN
        results_NNS were_VBD well_RB received_VBN and_CC may_MD have_VB improved_VBN patient_NN 's_POS
        compliance_NN and_CC interest_NN in_IN lipid_NN therapy_NN ,_, but_CC we_PRP did_VBD not_RB
        formally_RB assess_VB patient_NN knowledge_NN of_IN hyperlipidemia_NN goals_NNS ,_,
        treatment_NN ,_, and_CC side_NN effects_NNS ,_, nor_CC document_NN refill_NN
        frequency_NN ._.
        Some_DT studies_NNS suggest_VBP that_IN dialysis_NN patients_NNS with_IN low_JJ LDL_NNP
        cholesterol_NN levels_NNS have_VBP increased_VBN risk_NN of_IN mortality_NN vs_NNS ._.
        those_DT with_IN higher_JJR LDL_NNP cholesterol_NN levels_NNS [_NN 24_CD ]_NN ._. LDL_NNP
        cholesterol_NN and_CC conventional_JJ cardiac_JJ risk_NN factors_NNS are_VBP
        insensitive_JJ predictors_NNS of_IN CAD_NNP in_IN this_DT population_NN [_NN 25_CD ]_NN ,_,
        and_CC may_MD reflect_VB the_DT high_JJ frequency_NN of_IN malnutrition_NN [_NN 26_CD ]_NN
        and_CC established_VBN cardiovascular_JJ disease_NN [_NN 27_CD ]_NN ._. In_IN our_PRP$
        study_NN ,_, albumin_NN remained_VBD stable_JJ as_IN LDL_NNP cholesterol_NN levels_NNS
        declined_VBD ._.
        Although_IN the_DT guidelines_NNS for_IN lipid_NN therapy_NN in_IN HD_NNP patients_NNS
        are_VBP extrapolated_VBN from_IN the_DT general_JJ population_NN ,_, current_JJ
        recommendations_NNS are_VBP to_TO treat_VB high-risk_JJ patients_NNS to_TO a_DT target_NN
        LDL_NNP cholesterol_NN of_IN ≤_NN 100_CD mg_NN /_NN dl_NN ._. Most_JJS dialysis_NN patients_NNS in_IN
        the_DT United_NNP States_NNPS do_VBP not_RB meet_VB these_DT targets_NNS ._. Tonelli_NNP et_CC al_NN
        [_NN 16_CD ]_NN measured_VBD statin_NN use_NN in_IN dialysis_NN patients_NNS ,_, but_CC not_RB
        whether_IN target_NN LDL_NNP cholesterol_NN was_VBD achieved_VBN ._. Admittedly_RB ,_,
        lipid_NN lowering_VBG and_CC its_PRP$ benefits_NNS are_VBP less_RBR well_RB defined_VBN in_IN
        renal_JJ failure_NN explaining_VBG why_WRB nephrologists_NNS may_MD not_RB be_VB as_IN
        aggressive_JJ in_IN statin_NN prescribing_VBG [_NN 28_CD ]_NN ._. However_RB ,_, the_DT
        anticipated_VBN shortages_NNS of_IN nephrology_NN manpower_NN
        (_( nephrologists_NNS ,_, nurses_NNS ,_, physicians_NNS '_POS assistants_NNS ,_, dietitians_NNS )_)
        may_MD make_VB it_PRP more_RBR difficult_JJ in_IN the_DT future_NN to_TO achieve_VB
        therapeutic_JJ goals_NNS [_NN 29_CD ]_NN ._. Methods_NNP to_TO help_VB promote_VB
        appropriate_JJ use_NN of_IN statins_NNS and_CC other_JJ drug_NN therapy_NN would_MD be_VB
        beneficial_JJ ._. Pharmacists_NNP are_VBP not_RB routinely_RB assigned_VBN to_TO
        dialysis_NN units_NNS ,_, however_RB ,_, Manley_NNP ,_, et_CC al_NN [_NN 30_CD ]_NN showed_VBD that_IN
        every_DT dollar_NN spent_VBD on_IN pharmaceutical_JJ care_NN in_IN ESRD_NNP results_NNS
        in_IN a_DT savings_NNS of_IN $_$ 3_CD ._. 98_CD ._. A_DT recent_JJ American_NNP College_NNP of_IN
        Physicians-_NNP American_NNP Society_NNP of_IN Internal_NNP Medicine_NNP position_NN
        paper_NN speculates_NNS that_WDT pharmacist_NN participation_NN in_IN patient_NN
        care_NN beyond_IN patient_NN education_NN and_CC hospital_NN rounds_NNS will_MD be_VB
        time_NN consuming_NN for_IN physicians_NNS [_NN 31_CD ]_NN ._. In_IN reality_NN ,_,
        pharmacist_NN participation_NN in_IN the_DT collaborative_JJ management_NN of_IN
        conditions_NNS such_JJ as_IN hyperlipidemia_NN through_IN programs_NNS like_IN
        ours_PRP ,_, may_MD free_VB nephrologists_NNS '_POS time_NN for_IN other_JJ activities_NNS and_CC
        improve_VB patient_NN outcomes_NNS while_IN still_RB maintaining_VBG physician_NN
        control_NN of_IN therapy_NN ._. Yet_RB ,_, maintaining_VBG good_JJ communication_NN ,_,
        documentation_NN ,_, and_CC quality_NN assurance_NN is_VBZ essential_JJ ._.
        The_DT treatment_NN of_IN hyperlipidemia_NN is_VBZ readily_RB suited_VBN to_TO the_DT
        algorithmic_JJ ,_, multidisciplinary_JJ approach_NN used_VBN in_IN the_DT present_JJ
        study_NN ._. Moreover_RB ,_, similar_JJ programs_NNS could_MD be_VB employed_VBN for_IN
        management_NN of_IN other_JJ ESRD_NNP complications_NNS ,_, such_JJ as_IN
        hyperphosphatemia_NN and_CC anemia_NN ,_, further_JJ improving_NN outcomes_NNS in_IN
        dialysis_NN patients_NNS with_IN the_DT least_JJS possible_JJ impact_NN on_IN
        staffing_NN and_CC resources_NNS ._.
        Despite_IN editorial_NN speculation_NN that_IN nephrologists_NNS are_VBP
        "_'' late_JJ to_TO the_DT party_NN "_'' in_IN adoption_NN of_IN cardiovascular_JJ risk_NN
        reduction_NN measures_NNS [_NN 9_CD ]_NN ,_, underutilization_NN of_IN proven_VBN
        therapies_NNS is_VBZ not_RB unique_JJ to_TO nephrology_NN ._. The_DT National_NNP Academy_NNP
        of_IN Science_NNP 's_POS Institute_NNP of_IN Medicine_NNP reported_VBD that_IN our_PRP$ health_NN
        care_NN delivery_NN system_NN continues_VBZ to_TO suffer_VB from_IN many_JJ
        deficiencies_NNS ,_, such_JJ as_IN use_NN of_IN beta-blockers_JJ in_IN only_RB 50_CD %_NN of_IN
        patients_NNS with_IN myocardial_NN infarction_NN [_NN 32_CD ]_NN ._. The_DT percentage_NN
        in_IN dialysis_NN patients_NNS is_VBZ similar_JJ [_NN 2_CD ]_NN ._. Setting_VBG targets_NNS and_CC
        achieving_VBG them_PRP are_VBP quite_RB different_JJ things_NNS ._. Undoubtedly_NNP ,_, new_JJ
        methods_NNS for_IN assuring_VBG the_DT implementation_NN of_IN proven_VBN or_CC
        therapies_NNS are_VBP needed_VBN ._. The_DT present_JJ study_NN adds_VBZ new_JJ
        information_NN on_IN the_DT process_NN of_IN improving_VBG statin_NN use_NN and_CC
        other_JJ therapies_NNS that_WDT could_MD improve_VB outcomes_NNS in_IN dialysis_NN
        patients_NNS ._.
      
      
        Conclusions_NNP
        Text_NNP for_IN this_DT section_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Authors_NNP '_'' contributions_NNS
        RV_NN participated_VBD in_IN the_DT development_NN &_CC implementation_NN
        of_IN the_DT guideline_NN described_VBD in_IN the_DT study_NN ,_, collected_VBN data_NNS ,_,
        and_CC wrote_VBD &_CC edited_JJ the_DT manuscript_NN ._.
        KA_NNP supervised_JJ development_NN of_IN the_DT guideline_NN and_CC
        implementation_NN of_IN the_DT program_NN ,_, participation_NN in_IN literature_NN
        search_NN and_CC writing_VBG and_CC editing_NN the_DT manuscript_NN ._.
        PW_NNP supervised_JJ development_NN of_IN the_DT guideline_NN and_CC
        implementation_NN of_IN the_DT program_NN ,_, and_CC participated_VBD in_IN the_DT
        writing_VBG and_CC editing_NN of_IN the_DT manuscript_NN ._.
        RM_NNP participated_VBD in_IN the_DT development_NN and_CC implementation_NN of_IN
        the_DT guideline_NN ,_, and_CC editing_NN of_IN the_DT manuscript_NN ._.
        AS_NNP participated_VBD in_IN the_DT development_NN of_IN the_DT guideline_NN and_CC
        editing_NN of_IN the_DT manuscript_NN ._.
        CY_NNP participated_VBD in_IN the_DT development_NN and_CC implementation_NN of_IN
        the_DT guideline_NN ,_, statistical_JJ analysis_NN of_IN the_DT data_NNS ,_, and_CC
        writing_VBG and_CC editing_NN of_IN the_DT manuscript_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
